Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.53 |
| ▸ | FLT4 | P35916 | 3/20 | 0.50 |
| ▸ | FES | P07332 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.43 |
| ▸ | CSNK1G1 | Q9HCP0 | 5/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 6/20 | 0.42 |
| ▸ | PRKACA | P17612 | 6/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 6/20 | 0.42 |
| ▸ | GSK3A | P49840 | 6/20 | 0.42 |
| ▸ | GSK3B | P49841 | 6/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 6/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4023147 | 0.79 | MAPKAPK2 (0.67) | MAPKAPK2FLT4FESFGFR1KDR | |
| SCHEMBL1836724 | 0.77 | NAMPT (0.48) | — | |
| SCHEMBL12077354 | 0.77 | ROCK1 (0.43) | MAPKAPK2FLT4FESFGFR1KDR | |
| SCHEMBL1834699 | 0.77 | ROCK1 (0.43) | MAPKAPK2FLT4FESFGFR1KDR | |
| SCHEMBL20095660 | 0.75 | HDAC1 (0.61) | MAPKAPK2FLT4FESFGFR1KDR | |
| SCHEMBL1704032 | 0.75 | MAPKAPK2 (0.52) | MAPKAPK2FLT4FESFGFR1KDR | |
| SCHEMBL4029781 | 0.74 | FLT4 (0.62) | MAPKAPK2FLT4FESFGFR1KDR | |
| SCHEMBL4025437 | 0.74 | FLT4 (0.62) | MAPKAPK2FLT4FESFGFR1KDR | |
| SCHEMBL4364173 | 0.73 | FLT4 (0.79) | MAPKAPK2FLT4FESFGFR1KDR | |
| SCHEMBL12094461 | 0.73 | NPC1 (0.50) | HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006426-B2 | Squaric acid derivatives as inhibitors of the nicotinamide | TOPOTARGET A/S (DK) | 2015-04-14 | — | — | US | claimed |
| US-9006426-B2 | Squaric acid derivatives as inhibitors of the nicotinamide | TOPOTARGET A/S (DK) | 2015-04-14 | — | — | US | disclosed |
| US-9006426-B2 | Squaric acid derivatives as inhibitors of the nicotinamide | TOPOTARGET A/S (DK) | 2015-04-14 | — | — | US | disclosed |
| US-9006426-B2 | Squaric acid derivatives as inhibitors of the nicotinamide | TOPOTARGET A/S (DK) | 2015-04-14 | — | — | US | disclosed |
| US-20120225847-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | ONXEO DK, BRANCH OF ONXEO S.A., FRANCE (DK) | 2012-09-06 | — | — | US | disclosed |
| US-20120225847-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | ONXEO DK, BRANCH OF ONXEO S.A., FRANCE (DK) | 2012-09-06 | — | — | US | disclosed |
| US-20120225847-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | ONXEO DK, BRANCH OF ONXEO S.A., FRANCE (DK) | 2012-09-06 | — | — | US | disclosed |
| EP-2318369-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | TopoTarget A/S (DK) | 2011-05-11 | — | — | EP | disclosed |
| WO-2009156421-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | TOPOTARGET A/S (DK) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009156421-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | TOPOTARGET A/S (DK) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225847-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | SUCNR1, NAMPT, NAPRT | MAPKAPK2 4156/4885FLT4 2827/4885FES 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.